Published in Ther Adv Hematol on October 01, 2015
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | NCT00924326
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | NCT01475058
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood | NCT01497184
Infusion of Allogeneic Umbilical Cord Blood-Derived CD19-Specific T Cells | NCT01362452
CD19 Redirected Autologous T Cells for Hodgkin Lymphoma | NCT02277522
Study of Efficacy and Safety of CTL019 in Adult ALL Patients | NCT02167360
Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid. Am J Cancer Res (2016) 0.77
Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system. Oncotarget (2017) 0.75
Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Ther Adv Hematol (2016) 0.75
Like Angler Fish, CAARs Lure Their Prey. Mol Ther (2016) 0.75
Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia. Palliat Support Care (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Acute lymphoblastic leukaemia. Lancet (2008) 8.54
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2014) 5.42
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A (1989) 4.63
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol (2014) 4.37
The tumor lysis syndrome. N Engl J Med (2011) 4.29
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (2006) 3.85
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant (2010) 3.79
Acute lymphoblastic leukaemia. Lancet (2013) 3.44
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia (2008) 3.10
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Current concepts in the diagnosis and management of cytokine release syndrome. Blood (2014) 2.63
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood (2013) 2.39
The myth of the second remission of acute leukemia in the adult. Blood (2012) 2.26
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol (2014) 2.03
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol (2013) 1.88
Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol (2013) 1.88
Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87
How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology (2012) 1.66
Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (2014) 1.64
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood (2014) 1.52
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood (2012) 1.47
Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol (2009) 1.34
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One (2013) 1.32
Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther (2013) 1.21
Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr (2014) 1.19
IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol (2012) 1.16
CD19-CAR trials. Cancer J (2014) 1.09
Immune-based therapies for childhood cancer. Nat Rev Clin Oncol (2014) 1.04
Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis (2004) 1.00
Chimeric Antigen Receptor Therapy for B-cell Malignancies. J Cancer (2011) 0.96
Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep (2014) 0.89
Hematological cancer in 2011: New therapeutic targets and treatment strategies. Nat Rev Clin Oncol (2012) 0.88
Risk-adapted treatment of pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 0.86
T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2013) 0.86
When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia? Hematology Am Soc Hematol Educ Program (2012) 0.85
Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res (2014) 0.80
Advances in cellular therapy for the treatment of leukemia. Discov Med (2014) 0.78
Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2011) 0.78
Advances in T-cell therapy for ALL. Best Pract Res Clin Haematol (2014) 0.77
CD19CAR T cells: From humble beginnings to cancer immunotherapy's poster child. Cancer J (2014) 0.76